Rare Pediatric Tumors Dashboard

Result: 194 out of 519 (37.4%) matched to ClinicalTrials.gov

1. Development Stage is the strongest predictor

The further along the pipeline, the higher the chance of finding a match on CT.gov. Preclinical drugs match only 16% of the time — they are simply too early to have registered trials. Phase I jumps to 40%, Phase II is at 34%, while Phase III–IV reach 50–55%, and Approved drugs hit 56%. This is logical: preclinical candidates often haven't been registered on CT.gov yet.

2. Drug naming pattern is a strong signal

Drugs with digits and special characters in their names (internal lab codes like SC-CAR/CAR-16.21, FGF14 CART) are found less often (29% vs 38%). Conversely, drugs with INN-standard names (endings like -mab, -nib, -lib) match more often (30% vs 24%). This means: many of the unmatched entries are internal laboratory codes that aren't publicly registered.

3. Mechanism of Action shows clear differences

100% matched: Natural Killer Cells. Also high: NK cells (83%), Cancer vaccines (71%), Anti-PD-1 mAb (67%), HDAC inhibitors (63%). On the other end: ODC inhibitors — 0% (all 7 not found), and Radiopharmaceuticals at only 13%. Well-established, widely-studied mechanisms link to CT.gov far better than novel experimental ones.

4. Year of first results shows a moderate trend

Older drugs (2006–2014) have a higher match rate of ~55% — their trials have been published and indexed for years. The 2022–2027 range stabilizes around 34% with many early-stage experimental compounds. Beyond 2028, the rate drops to 28% — these are future projections for drugs still in early development.

5. Line of Therapy

Preclinical line matches at only 18% (not yet on CT.gov). Neoadjuvant hits 100% (though only 3 entries). The bulk — Second line (400 entries) — matches at 39%. First line does better at 46%.

6. Companies show no clear pattern

Large pharma (Novartis, Bayer) range 40–75%. Academic centres vary widely from 0% to 71%. Company alone is not a reliable predictor of CT.gov match.